Plaque Psoriasis
Conditions
Interventions
The group treated with nivolumab:None
Sponsors
Shanghai Skin Hospital
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1.Willing to participate in this study and sign the informed consent form; 2.Male or female aged =18 years; 3.Diagnosed with moderate-to-severe plaque psoriasis with a disease duration of =3 months, according to the 2023 Chinese Guidelines for the Diagnosis and Treatment of Psoriasis.
Exclusion criteria
Exclusion criteria: 1.Patients who do not meet the recommendations for switching biologics as outlined in the 2024 Chinese Guidelines for the Treatment of Psoriasis with Biologics and Small Molecule Drugs. 2.Presence of psoriasis forms other than chronic plaque type at screening or baseline (e.g., pustular, erythrodermic, or guttate psoriasis). 3.Drug-induced psoriasis. 4.Presence of other skin conditions that may interfere with psoriasis assessment, such as skin infections, as judged by the investigator. 5.History of inflammatory bowel disease or other ongoing active autoimmune diseases. 6.History of unstable malignancy within the past 5 years. 7.Severe cardiovascular, cerebrovascular, endocrine, or other systemic diseases considered by the investigator to be unsuitable for study participation. 8.Untreated or uncontrolled active infection. 9.Poor compliance or any other condition deemed by the investigator as inappropriate for trial participation.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| PASI 100 response rate at week 24 of treatment; | — |
Secondary
| Measure | Time frame |
|---|---|
| Psoriasis Area and Severity Index(PASI) 75/90;Psoriasis Area and Severity Index(PASI) =3;Psoriasis Area and Severity Index(PASI) =1;Investigator’s Global Assessment (PGA) 0/1;Relapse rate; | — |
Countries
China
Contacts
Public ContactYuling Shi
Shanghai Skin Hospital
Outcome results
None listed